Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by vikingguyon May 31, 2017 8:57pm

199 Views

Post# 26308978

RE:RE:RE:Big boys are watching

Thanks for posting Lee430, it was nice to read. Also, congrats on your TH position (its massive).

I'm curious what the end of Q1 has to do with your exit strategy. Are you assuming that Ibalizumab is approved in Q1? For me Ibalizumab will be approved by the latest December, if things go as they should. And if things do not go as they should, how do we know when it will be approved? Q1, Q2, Q3?????

Bullboard Posts

Options trading in a volatile macro environment